How it works: Medicines for NMOSD and MOGAD →

In development for MS or related diseases. No approval for these conditions is recorded in the bank.

Molecule type
Antibody
Mechanism (ChEMBL)
Interleukin-6 receptor alpha subunit inhibitor
Targets
Interleukin-6 receptor subunit alpha

Approvals

None recorded.

Safety communications

None recorded.

Trials

Key trials

Large trials with a reported result on their main goal.

  • TANGO

    Completed · Phase 2 / Phase 3 · NMOSD · Main goal met

Running now

Other trials (1)

Completed small trials, dose-finding studies and trials in other diseases.

For information only, not medical advice. Talk to your neurologist before changing treatment.

Hypotheses involving this medicine

Loading hypotheses…

Loading reviews and guidelines…

Lab studies

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error